Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

From X

@kevin__mak

Kevin Mak on X

$SPHR Update on my old friend Sphere. The recent sell off seems to be directly related to some sell-side rerating of the stock based on "soft data". I find that kind of interesting because the data has been soft for many months (see daily ticket sales chart below), and among investors that I talk to, this isn't a "surprise". (Realistically that's why the stock traded down from $170 to $130). So this "surprise, the data is weak, stock rerates down 25%" is interesting to me, but also reminds me: it's always extremely hard to figure out what the market has or hasn't "priced in". The issue with the "soft data" is that my (and many) original projections was that WoZ would trough at around 1.4-1.6m/day of sales in 2027. By the summer we observed levels of ~1.2m so that likely wasn't going to happen. Towards the end of the year, the data has inflected upwards, we're down YoY (expected, given less hype than the launch a year ago). Some of this is likely due to LV weakness in general, but I think that's a relatively small fraction of the story. Personally, I find this data interesting because A) I think it's largely meaningless to value the company B) I think the market overreacts to it I think the Sphere business is humming along extremely nicely. The concert business is consistently improving (higher numbers, better acts, more utilization). The ads and bookings businesses are healthy/growing, there are 2 (and probably more unannounced) additional Spheres working through production. What WOZ did was prove that a "hit film" could generate enormous interest/revenues/visitors to the Sphere. Whether it "levels off" at $1m/day, or $1.2m/day or $1.4m/day, doesn't matter that much because the longer term model is to consistently launch NEW films launch and generate $1.5-$2.5m/day. And they have somewhere between 2-3 new films coming out next year, and probably another 2-3 films in 2028. AI is cutting their speed (and cost) of making films dramatically. Overall I'm a buyer at these $100-$120 price levels (We're long via some short Nov $120P's that are currently in the money). Given recent price action, it's hard to say how the market reacts to the November earnings release, but I think the earnings picture has stabilized from here and the stock is setup for good fundamental catalysts driving earnings growth in 2027.
@ACapitalLP 2 clicks

A Capital on X

Two event-driven levered equities I’m thinking about this weekend: $XRX and $SVC. $XRX seems simple on paper. Monetize XFS, delever and unlock substantial equity value. But if it’s that obvious, why hasn’t Icahn’s guy done it in eight years? The recent TPG IP monetization suggests they’re willing to get creative, so what’s preventing an XFS transaction? $SVC is potentially more interesting. If the board accepts TKO’s $2bn hotel portfolio offer, you’re creating the remaining net lease portfolio at a very attractive valuation with significant equity torque from deleveraging. My biggest question is whether TKO actually has the financing commitments to close… Thoughts welcome.

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 18 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $110M
Triple S Special Situations Investing 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $110M
Value Investors Club

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…

VICR $9.7B
CV's Substack 28 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 10 clicks

Monte Investments Market Brief Vol. CXXXII

CoreWeave and neocloud peers face financing pressure, but sold-out GPU capacity and rising H100 and B200 rental rates support continued AI…

MYRG $4B
Monte Independent Investment Research 8 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 55 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.